Resources

Cognito Therapeutics Announces First Patient Enrollment in US Pivotal Study HOPE

The promising new Alzheimer's drugs to watch — and the far-out ideas that could reshape how we treat the disease

Startup’s Headset to Treat Alzheimer’s Will Undergo Wide Trial With Patients

Gamma frequency sensory stimulation in mild probable Alzheimer’s dementia patients: Results of feasibility and pilot studies

Cognito Therapeutics to Present Clinical Data Evaluating Gamma Frequency Neuromodulation in Alzheimer’s Disease at 2022 CTAD Conference

Cognito's light-and-sound therapy slows brain tissue atrophy in Alzheimer's study